| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC46947 | Fosgonimeton | Fosgonimeton is a hepatocyte growth factor receptor agonist (WO2017210489). |
|
| DC46948 | Gemnelatinib | Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer. |
|
| DC46949 | Terevalefim | Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor. |
|
| DC47018 | Vepafestinib | Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439). |
|
| DC47115 | Befotertinib | Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). |
|
| DC47121 | DDR2-IN-1 | DDR2-IN-1 is potent DDR2 inhibitor with an IC50 of 26 nM. DDR2-IN-1, compound 129, can be used for osteoarthritis research. |
|
| DC47129 | Zeteletinib | Zeteletinib (BOS-172738) shows selective inhibitory activity against RET, PDGFR, KIT, NTRK and FLT3 kinases. Zeteletinib has antitumor activity. |
|
| DC47271 | Tyrphostin 8 | Tyrphostin 8 is a tyrosine kinase, with an IC50 of 560 μM for EGFR kinase. Tyrphostin 8 is also a GTPase inhibitor. Tyrphostin 8 can inhibit the protein serine/threonine phosphatase calcineurin (IC50=21 μM). |
|
| DC47279 | Pegaptanib sodium | Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) . |
|
| DC47302 | AZD8601 | AZD8601 is an mRNA designed to produce vascular endothelial growth factor A (VEGF-A). AZD8601 accelerates diabetic wound healing. |
|
| DC47314 | TPX-0046 | TPX-0046 is a novel RET/SRC inhibitor with a mean IC50 of 17 nM for RETG810R in Ba/F3 cell proliferation assay.,RET [1]() SRC [1]() |
|
| DC47324 | Trk-IN-6 | Trk-IN-6 shows excellent in vitro potency on a panel of TRK mutants (IC50 = 0.2-0.7 nM). |
|
| DC47331 | AZ14145845 | AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy. |
|
| DC47332 | Antiallergic agent-1 | Antiallergic agent-1, a Src-family kinase inhibitor, may serve as a new valuable lead compound for future antiallergic drug discovery. |
|
| DC47592 | ITK/TRKA-IN-1 | ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively. |
|
| DC47657 | LT-850-166 | LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations. |
|
| DC47658 | FGFR-IN-1 | FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219). |
|
| DC47667 | EGFR/CSC-IN-1 | EGFR/CSC-IN-1 is a potential EGFR (IC50 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer treatment. |
|
| DC47668 | EGFR-IN-17 | EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. |
|
| DC47669 | EGFR-IN-18 | EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM). |
|
| DC47679 | Dyrk1A-IN-1 | Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers. |
|
| DC47703 | BPR1R024 Featured | BPR1R024 is an orally active and selective CSF1R inhibitor with IC50 of 0.53 nM. BPR1R024 specifically inhibits protumor M2-like macrophage survival with a minimal effect on antitumor M1-like macrophage growth. |
|
| DC47717 | TAK-020 Featured | TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate. |
|
| DC47718 | AS-1763 Featured | AS-1763 is an orally available, potent, and selective BTK inhibitor and shows excellent potency against both wild/C481S mutant BTKs with IC50 of 0.85 nM/0.99 nM. |
|
| DC47719 | BTK inhibitor 19 | BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM). |
|
| DC47760 | ALK-IN-13 | ALK-IN-13 is an ALK inhibitor, extracted from patent US20130225528A1, example 19. |
|
| DC47761 | ALK-IN-12 | ALK-IN-12 is a potent and orally active ALK inhibitor with an IC50 of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC50=20.3 and 90.6 nM). Antitumor activities. |
|
| DC47868 | Zeteletinib hemiadipate | Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib hemiadipate shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib hemiadipate has potent antitumor activity. |
|
| DC47902 | SH-1028 mesylate | SH-1028 (mesylate) is a selective and oral active inhibitor of EGFR with an IC50 of 18 nM. SH-1028 (mesylate) exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations. SH-1028 (mesylate) significantly inhibits proliferation of tumor cells with EGFR sensitive and resistant mutation. |
|
| DC47910 | S116836 | S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor (TKI), blocks both wild-type as well as T315I Bcr-Abl. S116836 potently inhibits the phosphorylation of BCR-ABL and induces apoptosis. S116836 inhibits growth of WT and T315I mutant BCR-ABL tumors and does not cause significant cardiotoxicity. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies. |
|
